Compare · ABT vs CTNM
ABT vs CTNM
Side-by-side comparison of Abbott Laboratories (ABT) and Contineum Therapeutics Inc. (CTNM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and CTNM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $163.94B, about 309.0x CTNM ($530.5M).
- Over the past year, ABT is down 30.1% and CTNM is up 242.0% - CTNM leads by 272.1 points.
- CTNM has been more active in the news (10 items in the past 4 weeks vs 7 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 5 for CTNM).
- Company
- Abbott Laboratories
- Contineum Therapeutics Inc.
- Price
- $93.86+0.66%
- $14.14+5.80%
- Market cap
- $163.94B
- $530.5M
- 1M return
- +9.57%
- +5.21%
- 1Y return
- -30.14%
- +241.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 7
- 10
- Recent ratings
- 25
- 5
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Latest CTNM
- SEC Form 4 filed by Director Miralles Gines Diego
- SEC Form 4 filed by Director Lyons-Williams Lori
- SEC Form 4 filed by Director Ware Olivia C
- SEC Form 4 filed by Director Schimmelpennink Evert B.
- SEC Form 4 filed by Director Ignelzi Troy A.
- SEC Form 4 filed by Director Brady Todd R.
- SEC Form 4 filed by Director Boyce Sarah
- Contineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)
- Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference